{"page": 1, "interactions": [{"interaction_id": "C0011812-C1873633", "slug": "dextroamphetamine-lisdexamfetamine", "agent": {"cui": "C0011812", "preferred_name": "Dextroamphetamine", "synonyms": ["Dextroamphetamine product", "dextroamphetamines", "(+)-Amphetamine", "d-Amphetamine", "d amphetamine", "amphetamines d", "d amphetamines", "Amphetamine (d-)", "dextro-Amphetamine", "dextro amphetamine", "Benzeneethanamine, alpha-methyl-, (S)-", "dexamfetamine", "Dexamphetamine", "psychostimulants dextroamphetamine", "(+)-alpha-Methylphenylethylamine", "(S)-(+)-beta-Phenylisopropylamine", "(S)-alpha-Methylbenzeneethanamine", "(S)-1-Phenyl-2-aminopropane", "(+)-(S)-amphetamine", "(S)-(+)-Amphetamine", "(S)-amphetamine", "(AlphaS)-alpha-methylbenzeneethanamine", "(+)-alpha-Methylphenethylamine", "(S)-1-Phenyl-2-propylamine", "Product containing dexamfetamine", "Dexamfetamine product"], "tradenames": [], "definition": "The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.", "ent_type": "supplement", "slug": "dextroamphetamine"}, "evidence": [{"paper": {"pid": "207297213", "title": "Metabolism, Distribution and Elimination of Lisdexamfetamine Dimesylate", "authors": [], "year": 2008, "venue": "Clinical drug investigation", "doi": "10.2165/0044011-200828120-00002", "pmid": 18991468, "fields_of_study": ["Medicine"], "animal_study": false, "human_study": true, "retraction": false, "clinical_study": true}, "sentences": [{"uid": 70099, "confidence": null, "paper_id": "207297213", "sentence_id": 17, "spans": [{"text": "Systemic exposure to", "cui": null}, {"text": "d-amphetamine", "cui": "C0011812"}, {"text": " was approximately 20-fold higher than systemic exposure to intact ", "cui": null}, {"text": "lisdexamfetamine", "cui": "C1873633"}, {"text": " dimesylate in healthy adults.", "cui": null}]}]}, {"paper": {"pid": "3541660", "title": "Chiral analysis of amphetamines in hair by liquid chromatography-tandem mass spectrometry: compliance-monitoring of attention deficit hyperactivity disorder (ADHD) patients under Elvanse\u00ae therapy and identification after controlled low-dose application.", "authors": [], "year": 2018, "venue": "Drug testing and analysis", "doi": "10.1002/dta.2208", "pmid": 28440070, "fields_of_study": ["Chemistry", "Medicine"], "animal_study": false, "human_study": true, "retraction": false, "clinical_study": false}, "sentences": [{"uid": 84692, "confidence": null, "paper_id": "3541660", "sentence_id": 9, "spans": [{"text": "Furthermore, it could be shown in a controlled study that", "cui": null}, {"text": "(S)-AMP", "cui": "C0011812"}, {"text": " can be detected after administration of even very low doses of ", "cui": null}, {"text": "lisdexamfetamine", "cui": "C1873633"}, {"text": " and dexamphetamine, which can be of interest in forensic toxicology and especially in drug-facilitated crime (DFC).", "cui": null}]}]}, {"paper": {"pid": "7813570", "title": "A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function", "authors": [], "year": 2016, "venue": "Therapeutic drug monitoring", "doi": "10.1097/FTD.0000000000000296", "pmid": 26926668, "fields_of_study": ["Medicine"], "animal_study": false, "human_study": true, "retraction": false, "clinical_study": false}, "sentences": [{"uid": 124157, "confidence": null, "paper_id": "7813570", "sentence_id": 9, "spans": [{"text": "Conclusions: There seems to be prolonged", "cui": null}, {"text": "D-amphetamine", "cui": "C0011812"}, {"text": " exposure after 30 mg ", "cui": null}, {"text": "LDX", "cui": "C1873633"}, {"text": " as renal impairment increases.", "cui": null}]}]}]}, {"interaction_id": "C1873633-C3818725", "slug": "lisdexamfetamine-adrenocorticotropic-hormone", "agent": {"cui": "C3818725", "preferred_name": "Adrenocorticotropic Hormone", "synonyms": ["Corticotropin", "ACTH", "Adrenocorticotropin"], "tradenames": [], "definition": "A hormone made in the pituitary gland. ACTH acts on the outer part of the adrenal gland to control its release of corticosteroid hormones. More ACTH is made during times of stress.", "ent_type": "supplement", "slug": "adrenocorticotropic-hormone"}, "evidence": [{"paper": {"pid": "53183893", "title": "Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study", "authors": [], "year": 2019, "venue": "The Journal of Steroid Biochemistry and Molecular Biology", "doi": "10.1016/j.jsbmb.2018.10.016", "pmid": 30381248, "fields_of_study": ["Medicine"], "animal_study": false, "human_study": true, "retraction": false, "clinical_study": false}, "sentences": [{"uid": 156741, "confidence": null, "paper_id": "53183893", "sentence_id": 5, "spans": [{"text": "", "cui": null}, {"text": "Lisdexamfetamine", "cui": "C1873633"}, {"text": " and d-amphetamine significantly enhanced plasma levels of ", "cui": null}, {"text": "adrenocorticotropic hormone", "cui": "C3818725"}, {"text": ", glucocorticoids (cortisol, cortisone, corticosterone, 11-dehydrocorticosterone, and 11-deoxycortisol), androgens (dehydroepiandrosterone, dehydroepiandrosterone sulfate, and \u03944-androstene-3,17-dione [androstenedione]), and progesterone (only in men) compared with placebo.", "cui": null}]}]}]}, {"interaction_id": "C0051821-C1873633", "slug": "andrographolide-lisdexamfetamine", "agent": {"cui": "C0051821", "preferred_name": "Andrographolide", "synonyms": ["(1R-(1-alpha(E(S)),4a-beta,5alpha,6alpha,8a-alpha))-3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-2(3H)-furanone", "3alpha,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid gamma-Lactone", "(3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one", "Andrographis"], "tradenames": [], "definition": "A labdane diterpenoid that is produced by the Andrographis paniculata plant, which has a broad range of therapeutic applications including anti-inflammatory and anti-platelet aggregation activities and potential antineoplastic properties. Since andrographolide has multiple therapeutic activities there are several proposed mechanisms of action for this agent. The anti-inflammatory effects of this agent appear to be related to the inhibition of nitric oxide (NO) production by macrophages. This agent may activate the NO/cyclic GMP pathway and inhibit both the phospholipase C gamma 2 (PLC gamma2)/protein kinase C (PKC) and PI3K/AKT-MAPK signaling pathways in activated platelets to inhibit platelet aggregation. In activated platelets, these three signaling pathways are downstream of integrin activation mediated by collagen binding and influence the association of fibrinogen with its receptors. Additionally, andrographolide may exert its anti-cancer activity through the induction of cell cycle arrest at G0/G1 phase and the stimulation of lymphocyte proliferation and activation. These processes could result in decreased proliferation of and increased immunocytotoxicity against tumor cells.", "ent_type": "supplement", "slug": "andrographolide"}, "evidence": [{"paper": {"pid": "235269798", "title": "Andrographolide blocks 50-kHz ultrasonic vocalizations, hyperlocomotion and oxidative stress in an animal model of mania.", "authors": [], "year": 2021, "venue": "Journal of psychiatric research", "doi": "10.1016/j.jpsychires.2021.05.042", "pmid": 34058655, "fields_of_study": ["Medicine"], "animal_study": true, "human_study": false, "retraction": false, "clinical_study": false}, "sentences": [{"uid": 250865, "confidence": null, "paper_id": "235269798", "sentence_id": 12, "spans": [{"text": "", "cui": null}, {"text": "LDX", "cui": "C1873633"}, {"text": " increased lipid peroxidation (LPO) levels in rat striatum and both lithium and ", "cui": null}, {"text": "ANDRO", "cui": "C0051821"}, {"text": " prevented this effect.", "cui": null}]}, {"uid": 250864, "confidence": null, "paper_id": "235269798", "sentence_id": 11, "spans": [{"text": "Repeated treatment with lithium or", "cui": null}, {"text": "ANDRO", "cui": "C0051821"}, {"text": " prevented these effects of ", "cui": null}, {"text": "LDX", "cui": "C1873633"}, {"text": " on 50-kHz USV and locomotor activity.", "cui": null}]}]}]}, {"interaction_id": "C0002860-C1873633", "slug": "androstenedione-lisdexamfetamine", "agent": {"cui": "C0002860", "preferred_name": "Androstenedione", "synonyms": ["Androstanedione", "androstenedione (ADD)", "Therapeutic Androstenedione", "delta4-Androstene-3,17-dione", "4-Androstene-3,17-dione", "delta-4-Androstenedione", "Delta 4-androstenedione", "Androst-4-ene-3,17-dione", "ADIONE - Delta 4-androstenedione", "ADD - androstanedione", "5alpha-Androstan-3,17-dione", "4-Androstenedione"], "tradenames": [], "definition": "A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.", "ent_type": "supplement", "slug": "androstenedione"}, "evidence": [{"paper": {"pid": "53183893", "title": "Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study", "authors": [], "year": 2019, "venue": "The Journal of Steroid Biochemistry and Molecular Biology", "doi": "10.1016/j.jsbmb.2018.10.016", "pmid": 30381248, "fields_of_study": ["Medicine"], "animal_study": false, "human_study": true, "retraction": false, "clinical_study": false}, "sentences": [{"uid": 156743, "confidence": null, "paper_id": "53183893", "sentence_id": 5, "spans": [{"text": "", "cui": null}, {"text": "Lisdexamfetamine", "cui": "C1873633"}, {"text": " and d-amphetamine significantly enhanced plasma levels of adrenocorticotropic hormone, glucocorticoids (cortisol, cortisone, corticosterone, 11-dehydrocorticosterone, and 11-deoxycortisol), androgens (dehydroepiandrosterone, dehydroepiandrosterone sulfate, and ", "cui": null}, {"text": "\u03944-androstene-3,17-dione", "cui": "C0002860"}, {"text": " [androstenedione]), and progesterone (only in men) compared with placebo.", "cui": null}]}]}]}, {"interaction_id": "C0011185-C1873633", "slug": "dehydroepiandrosterone-lisdexamfetamine", "agent": {"cui": "C0011185", "preferred_name": "Dehydroepiandrosterone", "synonyms": ["prasterone", "DHEA", "dehydroepiandrosterone (DHEA)", "Dehydroepiandrosterone product", "Androstenolone", "dehydroisoandrosterone", "Androst-5-en-17-one, 3-hydroxy-, (3beta)-", "Dehydro-3-epiandrosterone", "DHA - Dehydroepiandrosterone", "DHEA - Dehydroepiandrosterone", "Dehydroandrosterone", "Product containing dehydroepiandrosterone", "5-Androsten-3-beta-hydroxy-17-one", "3-beta-hydroxy-5-androsten-17-one", "3beta-hydroxyandrost-5-en-17-one", "3\u03b2-hydroxyandrost-5-en-17-one", "Therapeutic Dehydroepiandrosterone", "dheas", "17-Hormoforin"], "tradenames": [], "definition": "major C19 steroid produced by the adrenal cortex; also produced in small quantities in the testis and the ovary; dehydroepiandrosterone (DHEA) can be converted to testosterone; androstenedione; estradiol; and estrone; most of DHEA is sulfated (dehydroepiandrosterone sulfate) before secretion.", "ent_type": "supplement", "slug": "dehydroepiandrosterone"}, "evidence": [{"paper": {"pid": "53183893", "title": "Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study", "authors": [], "year": 2019, "venue": "The Journal of Steroid Biochemistry and Molecular Biology", "doi": "10.1016/j.jsbmb.2018.10.016", "pmid": 30381248, "fields_of_study": ["Medicine"], "animal_study": false, "human_study": true, "retraction": false, "clinical_study": false}, "sentences": [{"uid": 156742, "confidence": null, "paper_id": "53183893", "sentence_id": 5, "spans": [{"text": "", "cui": null}, {"text": "Lisdexamfetamine", "cui": "C1873633"}, {"text": " and d-amphetamine significantly enhanced plasma levels of adrenocorticotropic hormone, glucocorticoids (cortisol, cortisone, corticosterone, 11-dehydrocorticosterone, and 11-deoxycortisol), androgens (", "cui": null}, {"text": "dehydroepiandrosterone", "cui": "C0011185"}, {"text": ", dehydroepiandrosterone sulfate, and \u03944-androstene-3,17-dione [androstenedione]), and progesterone (only in men) compared with placebo.", "cui": null}]}]}]}, {"interaction_id": "C0033308-C1873633", "slug": "progesterone-lisdexamfetamine", "agent": {"cui": "C0033308", "preferred_name": "Progesterone", "synonyms": ["Progesterone product", "Therapeutic Progesterone", "progesterones", "Corpus Luteum Hormone", "Pregnenedione", "Pregn-4-ene-3,20-dione", "PRG - Progesterone", "(S)-Pregn-4-en-3,20-dione", "17alpha-Progesterone", "17\u03b1-progesterone", "Lutogynon", "(S)-Progesterone", "delta(4)-Pregnene-3,20-dione", "(S)-4-Pregnene-3,20-dione", "Product containing progesterone", "Delta4-pregnene-3,20-dione", "progestrogens progesterone", "PRG"], "tradenames": [], "definition": "The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.", "ent_type": "supplement", "slug": "progesterone"}, "evidence": [{"paper": {"pid": "53183893", "title": "Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study", "authors": [], "year": 2019, "venue": "The Journal of Steroid Biochemistry and Molecular Biology", "doi": "10.1016/j.jsbmb.2018.10.016", "pmid": 30381248, "fields_of_study": ["Medicine"], "animal_study": false, "human_study": true, "retraction": false, "clinical_study": false}, "sentences": [{"uid": 156744, "confidence": null, "paper_id": "53183893", "sentence_id": 5, "spans": [{"text": "", "cui": null}, {"text": "Lisdexamfetamine", "cui": "C1873633"}, {"text": " and d-amphetamine significantly enhanced plasma levels of adrenocorticotropic hormone, glucocorticoids (cortisol, cortisone, corticosterone, 11-dehydrocorticosterone, and 11-deoxycortisol), androgens (dehydroepiandrosterone, dehydroepiandrosterone sulfate, and \u03944-androstene-3,17-dione [androstenedione]), and ", "cui": null}, {"text": "progesterone", "cui": "C0033308"}, {"text": " (only in men) compared with placebo.", "cui": null}]}]}]}], "interactions_per_page": 50, "total": 6}